Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - CytomX Therapeutics, Inc. | ctmx-ex321_7.htm |
| EX-31.2 - EX-31.2 - CytomX Therapeutics, Inc. | ctmx-ex312_8.htm |
| EX-31.1 - EX-31.1 - CytomX Therapeutics, Inc. | ctmx-ex311_9.htm |
| EX-10.25 - EX-10.25_MK RETIREMENT AGREEMENT - CytomX Therapeutics, Inc. | ctmx-ex1025_992.htm |
| EX-10.24 - EX-10.24 - MK CONSULTING AGREEMENT - CytomX Therapeutics, Inc. | ctmx-ex1024_991.htm |
| 10-K - 10-K - CytomX Therapeutics, Inc. | ctmx-10k_20201231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-216567 and 333-228203) and Form S-8 (Nos. 333-207694, 333-209992, 333-215795, 333-223491, 333-229916 and 333-236711) of CytomX Therapeutics, Inc. of our report dated February 24, 2021, with respect to the financial statements of CytomX Therapeutics, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Redwood City, California
February 24, 2021